Step 1 topics → General Pathology → Oncogenes

Oncogenes

USMLE Step 1 trap: Confuses oncogene activation (dominant, one hit) with tumor suppressor loss (recessive, two hits). Oncogenes are dominant gain-of-function mutations; a single mutant allele is sufficient to promote malignancy.

Oncogenes are mutated or overexpressed versions of normal proto-oncogenes, and USMLE Step 1 tests them relentlessly — from pure recall to mechanistic reasoning to passage-based application. When activated, they push cells toward uncontrolled division regardless of normal signaling restraints. The classic associations — RAS, MYC, HER2, BCR-ABL — appear constantly, and you need to know not just the name but the molecular mechanism behind each. Step 1 tests oncogenes from three angles: which oncogene goes with which cancer, how the mutation actually drives proliferation, and given a translocation description, identify the cancer or predict drug sensitivity.

The biggest trap on Step 1 is conflating oncogenes with tumor suppressors. Oncogenes are dominant gain-of-function — one mutant allele is enough. Tumor suppressors are recessive loss-of-function — you need to knock out both copies. Students who blur this distinction consistently miss questions asking whether a mutation is 'one hit' or 'two hit.' A second major trap is misremembering mechanisms: RAS mutations don't cause protein overproduction; they lock the existing protein in an always-ON state by impairing GTPase activity. BCR-ABL is a tyrosine kinase, not a transcription factor — a distinction that matters when questions ask why imatinib works.

Translocations are their own sub-category and the exam loves them. You need to know the chromosome numbers, the genes involved, and the resulting cancer for at least four or five classic translocations cold. Burkitt lymphoma's t(8;14) moving c-MYC next to immunoglobulin heavy chain promoters is the prototype. If you can explain why that translocation causes overexpression — not mutation of c-MYC — you'll handle any variation the question throws at you.

From real student decks
81%have cards covering this topic
65%have mature cards

Common misconceptions

Common mistake
Wrong: Oncogenes require loss of both alleles (like tumor suppressors) to drive cancer.
Right: Oncogenes are dominant gain-of-function mutations; a single mutant allele is sufficient to promote malignancy.
Oncogenes follow a dominant gain-of-function model: one mutated allele produces a hyperactive or constitutively active protein that overrides normal growth controls, so the second allele doesn't matter. This is the opposite of tumor suppressors, where both alleles must be inactivated (Knudson's two-hit model) before the braking function is lost. If a question describes a single mutation that drives proliferation, that's an oncogene — not a tumor suppressor.
Common mistake
Wrong: The BCR-ABL fusion protein in CML acts as a transcription factor.
Right: BCR-ABL is a constitutively active tyrosine kinase that drives uncontrolled cell proliferation.
BCR-ABL is a fusion tyrosine kinase, not a transcription factor. The t(9;22) translocation fuses BCR to ABL, and the resulting protein has constitutively active kinase activity that continuously phosphorylates downstream proliferation signals — it never waits for a ligand to turn it on. This is exactly why imatinib (a tyrosine kinase inhibitor) works: block the kinase domain, block the signal. If you were thinking transcription factor, imatinib's mechanism wouldn't make sense.
Common mistake
Wrong: Students associate c-MYC overexpression with CML rather than Burkitt lymphoma.
Right: c-MYC overexpression via t(8;14) translocation is the hallmark of Burkitt lymphoma, not CML.
c-MYC overexpression via t(8;14) is the defining molecular event of Burkitt lymphoma, not CML. The translocation places c-MYC (chromosome 8) next to the immunoglobulin heavy chain enhancer (chromosome 14), massively upregulating transcription of this growth-promoting gene. CML is defined by BCR-ABL from t(9;22) — a completely different oncogene and mechanism. Mixing these up is one of the most common translocation errors on Step 1.
Common mistake
Wrong: RAS oncogene mutations cause overproduction of the RAS protein.
Right: RAS oncogene mutations impair intrinsic GTPase activity, locking RAS in a constitutively active GTP-bound state.
RAS mutations don't make more RAS protein — they break the protein's built-in off switch. Normal RAS cycles between an active GTP-bound state and an inactive GDP-bound state, with GTPase activity cleaving GTP to GDP to turn itself off. Oncogenic RAS mutations (most commonly G12V or G12D in K-RAS) impair this GTPase activity, so RAS gets stuck in the GTP-bound 'on' state and continuously signals downstream proliferation pathways. This distinction matters because targeted therapy against RAS has to address this locked-on conformation, not simply reduce protein levels.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the definition of an oncogene and the four main activation mechanisms: point mutation, gene amplification, chromosomal translocation, and viral insertion — and recognize which mechanism applies to a given oncogene scenario.
  2. For each high-yield oncogene (RAS, MYC, HER2/ERBB2, BCR-ABL, BRAF, ALK, KIT, RET, JAK2), know the associated cancer(s) and the specific molecular mechanism by which the mutant protein drives proliferation.
  3. Given a chromosomal translocation (e.g., t(8;14), t(9;22), t(14;18)), identify the oncogene involved, the cancer it defines, and explain the mechanistic consequence of bringing that gene under a new promoter or creating a fusion protein.

Can you avoid these mistakes?

A patient with CML carries the Philadelphia chromosome translocation. A classmate says BCR-ABL works by binding DNA and activating transcription of growth genes. How would you correct this, and what is the actual mechanism that makes imatinib an effective treatment?
You read a vignette describing a mutation in K-RAS codon 12 in a pancreatic adenocarcinoma. The question asks whether this is a gain-of-function or loss-of-function mutation, and how many alleles need to be affected. What do you answer, and why?
Match each translocation to its cancer and the oncogene involved: t(8;14), t(9;22), t(14;18). For each, state what the translocation does mechanistically — does it create a fusion protein, or does it relocate a gene under a new promoter?
A biopsy shows amplification of ERBB2 (HER2) in a breast cancer sample. A classmate says this is the same mechanism as RAS mutation. Explain why these are different activation mechanisms and what clinical implication the HER2 amplification has for treatment selection.

Related topics

Hallmarks of Cancer Reversible vs Irreversible Cell Injury Types of Necrosis Apoptosis (Intrinsic and Extrinsic Pathways) Cell Adaptations (Atrophy, Hypertrophy, Hyperplasia, Metaplasia, Dysplasia)

See how your Anki deck covers this topic.

Upload your deck for a free audit →